| Date Filed | Type | Description |
| 08/24/2023 |
4
| Svoronos Dawn (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Sold 25,000 shares
@ $38.7, valued at
$967.5k
|
|
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
4
| Gover Justin D. (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 28,000 options to buy
@ $38.39, valued at
$1.1M
|
|
| 08/10/2023 |
3
| Gover Justin D. (Director) has filed a Form 3 on Xenon Pharmaceuticals Inc. |
| 08/10/2023 |
4
| Cannon Gillian (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 28,000 options to buy
@ $38.39, valued at
$1.1M
|
|
| 08/10/2023 |
3
| Cannon Gillian (Director) has filed a Form 3 on Xenon Pharmaceuticals Inc. |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/02/2023 |
4
| AZAB MOHAMMAD (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| PATOU GARY (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| GANNON STEVEN (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| Svoronos Dawn (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| GAROFALO ELIZABETH A. (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| PIMSTONE SIMON N. (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/02/2023 |
4
| Machado Patrick (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 18,475 options to buy
@ $38.96, valued at
$719.8k
|
|
| 06/01/2023 |
4
| PIMSTONE SIMON N. (Director) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Sold 18,006 shares
@ $38.63, valued at
$695.6k
Sold 19,000 shares
@ $39.9, valued at
$758.1k
Sold 12,000 shares
@ $38.53, valued at
$462.4k
Exercised 29,835 shares
@ $9.85, valued at
$293.9k
Paid exercise price by delivering 6,165 shares
@ $38.37, valued at
$236.6k
Sold 23,670 shares
@ $38.81, valued at
$918.6k
Paid exercise price by delivering 23,144 shares
@ $38.37, valued at
$888k
Sold 26,856 shares
@ $38.69, valued at
$1M
Paid exercise price by delivering 1,860 shares
@ $38.53, valued at
$71.7k
Sold 7,458 shares
@ $38.97, valued at
$290.6k
Paid exercise price by delivering 20,745 shares
@ $38.53, valued at
$799.3k
|
|
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/26/2023 |
4
| MORTIMER IAN (PRESIDENT & CEO) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Exercised 42,592 shares
@ $9.44, valued at
$402.1k
Paid exercise price by delivering 7,310 shares
@ $41.84, valued at
$305.9k
Sold 17,069 shares
@ $41.44, valued at
$707.3k
Exercised 20,576 shares
@ $9.85, valued at
$202.7k
Paid exercise price by delivering 3,902 shares
@ $41.84, valued at
$163.3k
Sold 13,179 shares
@ $41.37, valued at
$545.2k
Exercised 6,172 shares
@ $9.85, valued at
$60.8k
Paid exercise price by delivering 1,171 shares
@ $41.84, valued at
$49k
Sold 1,407 shares
@ $41.49, valued at
$58.4k
Exercised 42,592 options to buy
@ $0
Exercised 20,576 options to buy
@ $0 |
|
| 05/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2023 |
4
| KENNEY CHRISTOPHER JOHN (Chief Medical Officer) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Sold 700 shares
@ $35.01, valued at
$24.5k
|
|
| 03/14/2023 |
4
| Von Seggern Christopher (Chief Commercial Officer) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 90,000 options to buy
@ $34.18, valued at
$3.1M
|
|
| 03/14/2023 |
4
| ROBIN SHERRINGTON (EVP, Strategy & Innovation) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 75,000 options to buy
@ $34.18, valued at
$2.6M
|
|
| 03/14/2023 |
4
| DiFabio Andrea (Chief Legal Officer) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 45,000 options to buy
@ $34.18, valued at
$1.5M
|
|
| 03/14/2023 |
4
| MORTIMER IAN (PRESIDENT & CEO) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 380,000 options to buy
@ $34.18, valued at
$13M
|
|
| 03/14/2023 |
4
| KENNEY CHRISTOPHER JOHN (Chief Medical Officer) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 120,000 options to buy
@ $34.18, valued at
$4.1M
|
|
| 03/14/2023 |
4
| EMPFIELD JAMES R. (EVP, Drug Discovery) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 75,000 options to buy
@ $34.18, valued at
$2.6M
|
|
| 03/14/2023 |
4
| AULIN SHERRY (CFO) has filed a Form 4 on Xenon Pharmaceuticals Inc.|
Txns:
| Granted 120,000 options to buy
@ $34.18, valued at
$4.1M
|
|
|